← 返回

黑色素瘤进展:治愈是否在望?

英文原题:Melanoma update: is a cure now in sight?

查看英文原题

Melanoma update: is a cure now in sight?

PubMed 2025/06/19(内容时间) Intern Med J Q2 · IF 1.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

黑色素瘤是最具侵袭性的皮肤癌之一,由于其高转移潜力和对传统治疗的耐药性,构成了重大的全球健康问题。本综述探讨了黑色素瘤治疗的最新进展,特别是靶向治疗和免疫治疗的影响,这些治疗显著延长了晚期黑色素瘤患者的生存期并改善了其生活质量。此外,免疫检查点抑制剂与癌症疫苗或针对BRAF突变的靶向治疗的创新联合及序贯策略,标志着一个有前景的方向。本文还涵盖了TIL(肿瘤浸润淋巴细胞)、溶瘤病毒治疗和个性化癌症疫苗开发的最新进展,强调了精准医学在实现定制化、有效治疗中的作用。尽管取得了这些进展,挑战依然存在,包括耐药性以及需要可靠的生物标志物来预测治疗反应和筛选患者。本综述强调了研究和临床试验中持续不断的努力,以完善治疗策略、改善更广泛人群的治疗结局,并最终朝着治愈黑色素瘤的方向迈进。

展开英文摘要原文

Melanoma, one of the most aggressive skin cancers, poses a significant global health concern due to its high metastatic potential and resistance to conventional treatments. This review explores recent advancements in melanoma treatment, particularly the impact of targeted therapies and immunotherapies which have significantly extended survival and improved the quality of life for advanced melanoma patients.

Additionally, the innovative combination and sequential strategies, with immune checkpoint inhibitors and cancer vaccines or targeted therapies against BRAF mutations, mark a promising direction. Recent advances in tumour infiltrating lymphocytes and oncolytic virus therapy and personalised cancer vaccine development are also covered, highlighting the role of precision medicine in achieving tailored, effective treatments.

Despite these advancements, challenges persist, including drug resistance and the need for reliable biomarkers to predict treatment response and select patients. This review underscores the ongoing efforts in research and clinical trials to refine therapeutic strategies, improve treatment outcomes for a larger population detection and, ultimately, advance towards a cure for melanoma.

论文信息

作者
Liaqat S、Khattak MA
单位
Department of Medical Oncology, Fiona Stanley Hospital, Perth, Western Australia, Australia.Australia
文献类型
综述
期刊
Internal medicine journal2025 Aug
原文标识
PubMed 40536073 · DOI 10.1111/imj.70085